GENERAL CHARACTERISTICS AND TREATMENT OPTIONS OF THE PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (original) (raw)
Gastrointestinal Stromal Tumors: Case Series of 29 Patients Defining the Role of Imatinib Prior to Surgery
Supreeta Arya
2012
View PDFchevron_right
CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate
Matias Chacon, Enrique Roca
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005
View PDFchevron_right
Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib
Michael Burgess
Annals of Surgical Oncology, 2007
View PDFchevron_right
Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST
Marco Fiore
Annals of Surgery, 2007
View PDFchevron_right
The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness
Evangelos Efstathios Visvardis
Surgical Oncology, 2005
View PDFchevron_right
Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients
Jan Andersson
British journal of cancer, 2003
View PDFchevron_right
Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
Nicholas Stylianides, Muntzer Mughal
World Journal of Surgical Oncology, 2008
View PDFchevron_right
Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall
Maria Debiec-Rychter
Histopathology, 2005
View PDFchevron_right
Treatment of non-resectable and metastatic gastrointestinal stromal tumors: experience with the use of tyrosine kinase inhibitors in a third level hospital in Mexico
Samuel Rivera
Journal of Gastrointestinal Oncology, 2016
View PDFchevron_right
Consensus meeting for the management of gastrointestinal stromal tumors * Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
Joan Maurel, George Demetri
Annals of Oncology, 2005
View PDFchevron_right
Surgical Treatment of Gastrointestinal Stromal Tumors Located in the Stomach in the Imatinib Era
Annemieke Cats
American Journal of Clinical Oncology, 2013
View PDFchevron_right
Current management of gastrointestinal stromal tumors – A comprehensive review
Dr. Naveen Solanki
International Journal of Surgery, 2012
View PDFchevron_right
Imatinib and gastrointestinal stromal tumor (GIST): a selective targeted therapy
JORGE APARICIO
Revista Espanola De Enfermedades Digestivas, 2004
View PDFchevron_right
Gastrointestinal stromal tumours: Clinical overview, surgery and recent advances in imatinib mesylate therapy
G.eorges F Samelis
European Journal of Surgical Oncology (EJSO), 2007
View PDFchevron_right
SURGERY FOR GASTROINTESTINAL STROMAL TUMOUR IN THE POST-IMATINIB ERA
susan neuhaus
Anz Journal of Surgery, 2005
View PDFchevron_right
Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours
Claire Hulme
Health technology assessment (Winchester, England), 2010
View PDFchevron_right
A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec™)
Karina Balan
International Journal of Surgery, 2005
View PDFchevron_right
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Karla Ballman
The Lancet, 2009
View PDFchevron_right
A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST)
Martin Robinson
Sarcoma, 2002
View PDFchevron_right
Gastrointestinal stromal tumour treated with neoadjuvant imatinib
Paul Waring
Journal of Clinical Pathology, 2005
View PDFchevron_right
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience
Paweł Nyckowski
Annals of Surgical Oncology, 2013
View PDFchevron_right
Two cases of complete response after imatinib mesylate treatment of advanced GIST
Sousanna-Maria Nikolaou
Anticancer research
View PDFchevron_right
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial
Giuliano Ramadori
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015
View PDFchevron_right
Management of malignant gastrointestinal stromal tumours
Sandra Silberman
The Lancet Oncology, 2002
View PDFchevron_right
Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib as Adjuvant Therapy—A Retrospective Chart Extract-Based Approach
Annie Guerin
Journal of Gastrointestinal Cancer, 2012
View PDFchevron_right
Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
Miin-fu Chen, Chun-nan Yeh
BMC gastroenterology, 2006
View PDFchevron_right
Advanced gastrointestinal stromal tumors: 10-years experience from a tertiary care centre
Nida Iqbal
Tropical Gastroenterology, 2015
View PDFchevron_right